Our product areas

Our portfolio is made up of Vaccines, Specialty Medicines and General Medicines. These are the three different types of products we create to prevent and treat disease.

Health impact

Human tech image

We prevent and treat disease with vaccines, specialty and general medicines. We focus on the science of the immune system and the use of new platform and data technologies, investing in four core therapeutic areas (infectious diseases, HIV, respiratory/immunology and oncology). Our Ahead Together strategy means intervening early to prevent and change the course of disease, helping to protect people and support healthcare systems. We’re confident in our future. With our strong momentum and improving outlook for sustained growth through the decade, we're confident in our ability to deliver human health impact at scale, worldwide.

  • 1.3 billion people with our vaccines
  • 40 million people with specialty medicines
  • 700 million people with our general medicines
  • 1.3 billion people through our work in Global Health, including product donations


Shingles Science Image

Vaccines help protect people from infectious diseases at every stage of life. Our portfolio of marketed vaccines is the broadest in the industry. It includes more than 20 vaccines that help protect people around the world from a range of diseases and infections throughout their lives. For many decades our vaccines have protected millions from diseases like whooping cough, polio and measles. Today we deliver approximately 1.5 million vaccine doses daily, and 4 out of 10 infants born each year receive at least one GSK vaccine. We are proud of the impact our vaccines continue to have on the health of hundreds of millions of people around the world.

We aim to reach 1.3 billion people with vaccines, a significant contribution to our overall ambition to positively impact the health of 2.5 billion people by the end of the decade.

Specialty medicines

HIV Science Image

Specialty medicines are prescribed by specialist healthcare practitioners. Our portfolio of specialty medicines prevents and treats diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Many are first or best-in-class. Our specialty medicines is focused on four therapeutic areas: infectious diseases, HIV, respiratory/immunology and oncology. We’re leaders in infectious diseases and HIV innovation and we’re building our positions in immunology and oncology. 

We aim to reach 40 million people with our specialty medicines, a significant contribution to our overall ambition to have a positive impact on the health of 2.5 billion people by the end of the decade.

General medicines

Escherichia Coli (E. Coli) Bacteria Science Image

General medicines are usually prescribed in primary care or community settings by general healthcare practitioners. General medicines include our inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases, in a portfolio which includes pre-launch R&D assets, growth and established products.  Every day, our general medicines improve health and make life better for millions all over the world and our portfolio of more than 150 primary care products supplied in 112 countries worldwide.

Our supply chain

Our operations span the value chain from identifying, researching, developing and testing groundbreaking discoveries, to regulatory approval, manufacturing and commercialisation. Getting our vaccines and medicines to patients who need them is critical to how we improve health around the world. Our global network of 37 vaccines and medicines manufacturing sites enabled us to produce and deliver 2.3 billion packs of medicines and doses of vaccines in 2023.

We make sure that products are manufactured as efficiently as possible and meet the strictest quality standards. The highest quality standards are ensured during each step of the vaccine production process, including vaccine components, facilities and equipment, people training, qualification, certification and storage. Each of our vaccines products is produced manufactured to the same quality standard, regardless of where in the world the vaccine it will be used.

We've built an agile network, with the capacity and capability to bring the next generation of medicines to patients all over the globe.